Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

#RemoteDetailing

- PMLiVE

Russia claims its COVID-19 vaccine is over 90% effective

Interim results come from first 16,000 participants to receive two doses of the vaccine

- PMLiVE

Sinovac’s late-stage COVID-19 vaccine trial paused in Brazil

Health regulator Anvisa reports that pause is due to severe adverse event

- PMLiVE

Creative med affairs and bridging the healthcare gap

Within the healthcare industry, any patient-facing activity has traditionally been the domain of marketing teams – be that brand marketing or marketing individual products. Recently, however, a trend has emerged...

Page & Page Health

- PMLiVE

NHS asked to ‘ready’ itself to provide Pfizer’s COVID-19 vaccine

Health Secretary Matt Hancock expects widespread roll-out early next year

- PMLiVE

Eli Lilly’s COVID-19 antibody scores FDA emergency use approval

Drug authorised to treat mild-to-moderate COVID-19

How can pharma align its brand strategy with the NHS Reset?

Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era

Wilmington Healthcare

- PMLiVE

Novo Nordisk set to acquire Emisphere Technology for $1.8bn

Danish pharma will acquire all outstanding shares in Emisphere

- PMLiVE

Pfizer, BioNTech’s COVID-19 vaccine prevents 90% of infections in initial late-stage study data

Preliminary results could warrant regulatory approval soon

- PMLiVE

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November

- PMLiVE

FDA advisory committee overwhelmingly votes no on Biogen’s aducanumab

Path to approval looks increasingly difficult for potential Alzheimer’s treatment

- PMLiVE

Gilead’s remdesivir not included in WHO’s COVID-19 drug scheme

Remdesivir not included as a priority drug, Reuters reports

- PMLiVE

Novartis’ canakinumab failed to improve survival in COVID-19 study

Swiss pharma company had been studying drug in hospitalised COVID-19 patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links